Edition:
United States

Aceto Corp (ACET.O)

ACET.O on Nasdaq

15.31USD
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
$15.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
330,293
52-wk High
$25.98
52-wk Low
$14.31

Latest Key Developments (Source: Significant Developments)

Aceto's unit launches Capecitabine Tablets, 150 & 500 MG
Tuesday, 28 Mar 2017 10:18am EDT 

Aceto Corp :Unit, Rising Pharmaceuticals launched Capecitabine tablets, 150 & 500 MG, AB-rated generic version of Xeloda tablets from Hoffman La Roche.  Full Article

Aceto reports Q2 loss per share $0.02
Thursday, 2 Feb 2017 05:05pm EST 

Aceto Corp - : Aceto reports fiscal 2017 second quarter results . Q2 adjusted non-gaap earnings per share $0.24 . Q2 loss per share $0.02 . Q2 sales $125.6 million versus I/B/E/S view $133.2 million . Q2 earnings per share view $0.30 -- Thomson Reuters I/B/E/S . Now expect Aceto's fiscal year 2017 sales growth to be in mid-to-high teen percentage range . Now expect Aceto's fiscal year 2017 non-gaap adjusted EPS to be roughly even with fiscal 2016 . Says still expect to launch 7 to 10 rising generic products during second half of fiscal 2017 . On a gaap basis, fiscal year 2017 EPS is expected to be below last year by roughly 45 pct .Fy2017 earnings per share view $1.57, revenue view $667.9 million -- Thomson Reuters I/B/E/S.  Full Article

Verdezyne signs distribution agreement with Aceto Corp
Wednesday, 5 Oct 2016 08:03am EDT 

Aceto Corp : BIOLON DDDA will be produced by verdezyne and will be distributed in United States Of America by Aceto .Verdezyne signs distribution agreement with Aceto Corporation.  Full Article

Aceto reports Q4 EPS $0.23
Thursday, 25 Aug 2016 05:42pm EDT 

Aceto Corp : Aceto reports fiscal 2016 fourth quarter and record full year results . Q4 adjusted non-gaap earnings per share $0.35 . Q4 earnings per share $0.23 . Q4 earnings per share view $0.39 -- Thomson Reuters I/B/E/S . Qtrly net sales of $135.4 million versus $146.6 million, a 7.6% decrease . "regarding 2017, we are expecting to grow both sales and net income" . For fiscal 2017, expecting both sales and non-gaap adjusted earnings per share to grow in mid-single digit percentage range . For fiscal 2017 expecting gaap earnings per share growing at a somewhat slower rate .Q4 revenue view $146.7 million -- Thomson Reuters I/B/E/S.  Full Article

Aceto's board increases qtrly dividend by 8.3 pct to $0.065/share
Thursday, 25 Aug 2016 03:30pm EDT 

Aceto Corp : Aceto board of directors increases quarterly cash dividend by 8.3 pct .Board of directors has increased its regular quarterly dividend to $0.065 per common share.  Full Article

Aceto Corporation board of directors declares quarterly cash dividend
Thursday, 4 Feb 2016 01:22pm EST 

Aceto Corporation:Board of Directors has declared a regular quarterly dividend of $0.06 per common share.Quarterly cash dividend will be distributed on March 25 to shareholders of record date as of March 11.  Full Article

Aceto Corporation announces the pricing of its $125 million convertible notes offering
Wednesday, 11 Nov 2015 12:34am EST 

ACETO Corporation:Says the pricing of $125 million aggregate principal amount of convertible senior notes due 2020 in a private placement to qualified institutional buyers.ACETO has also granted the initial purchasers of the notes an option to purchase up to an additional $18.75 million aggregate principal amount of the notes within 13 days of the initial closing of the notes offering, solely to cover over-allotments.The sale of the notes to the initial purchasers is expected to settle on November 16, 2015, subject to customary closing conditions, and is expected to result in approximately $120.5 million in net proceeds to ACETO.Wells Fargo Securities, LLC and J.P. Morgan Securities LLC are acting as bookrunners.  Full Article

Aceto Corporation subsidiary, Rising Pharmaceuticals, acquires three FDA-approved ANDAs From Endo International plc
Monday, 28 Sep 2015 08:01am EDT 

Aceto Corporation:ACETO subsidiary, Rising Pharmaceuticals, acquires three FDA-approved ANDAs From Endo International plc.To buy 3 ANDAS from a subsidiary of Endo International plc for the products methimazole tablets, glycopyrrolate tablets and meclizine tablets.  Full Article

Aceto Subsidiary, Rising Pharmaceuticals acquires three FDA approved Ophthalmic ANDAs from Nexus Pharmaceuticals
Tuesday, 15 Sep 2015 09:12am EDT 

ACETO Corp's Rising Pharmaceuticals, Inc:Says has completed the purchase of three ANDAs for the products Ciprofloxacin Ophthalmic Solution 3%, Levofloxacin Ophthalmic Solution 0.5%, and Diclofenac Sodium Ophthalmic Solution 0.1% from Nexus Pharmaceuticals.Transaction enables Rising to gain full ownership of the ANDAs as well as increased margins.  Full Article

Aceto Corp gives FY 2016 outlook
Thursday, 10 Sep 2015 05:00pm EDT 

Aceto Corp:Expects to achieve mid-single digit revenue growth and low-double digit net income growth in FY 2016.  Full Article

More From Around the Web

BRIEF-Aceto's unit launches Capecitabine Tablets, 150 & 500 MG

* Unit, Rising Pharmaceuticals launched Capecitabine tablets, 150 & 500 MG, AB-rated generic version of Xeloda tablets from Hoffman La Roche Source text for Eikon: Further company coverage: